Mechanical circulatory support pathways that maximize post-heart transplant survival

Tara Karamlou, Jill Gelow, Brian S. Diggs, Frederick (Fred) Tibayan, James Mudd, Steven W. Guyton, Matthew Slater, Howard Song

    Research output: Contribution to journalArticle

    24 Citations (Scopus)

    Abstract

    Background: Heart transplant (HTx) recipients reach transplantation through increasing numbers of support pathways, including transition from one pathway to another. Outcomes of patients successfully bridged with various support pathways are unknown. We sought to identify mechanical circulatory support pathways that maximize survival after HTx. Methods: A supplemented United Network Organ Sharing Dataset tracked status 1 HTx outcomes from 2000 to 2010. Recipients were grouped based on support pathway before HTx, including those transitioning from one pathway to another. Multivariable factors for time-related death were sought using Cox proportional hazard regression models. Results: We identified 13,250 status 1 HTx recipients. Initial support pathways were inotropes (n = 7,607), left ventricular assist device (LVAD [n = 4,034]), intraaortic balloon pump (n = 729), biventricular assist device (n = 521), extracorporeal membrane oxygenation (ECMO [n = 316]), and right ventricular assist device (n = 43). Multivariable analysis demonstrated that LVAD use conferred a survival advantage (hazard ratio [HR] 0.71; p <0.001), whereas all other support pathways, including inotropes (HR 1.1; p = 0.02), right ventricular assist device (HR 1.9; p = 0.01), and ECMO (HR 2.2; p <0.001) increased the risk of post-HTx death. Support pathway transition (both escalation and reduction) occurred in 2,175 patients. Patients who transitioned from either ECMO or biventricular assist device support at listing to LVAD-only support at HTx had improved post-HTx survival that was comparable to patients who had LVAD-only therapy throughout their course (p = 0.74). Conclusions: The LVAD supported HTx recipients have better posttransplant survival than patients after all other mechanical support pathways. Survival after HTx is optimized when ECMO or biventricular assist device support can be transitioned to LVAD-only support. Our findings should aid clinical decision making and inform organ allocation policy development intended to maximize societal benefits of HTx.

    Original languageEnglish (US)
    Pages (from-to)480-485
    Number of pages6
    JournalAnnals of Thoracic Surgery
    Volume95
    Issue number2
    DOIs
    StatePublished - Feb 2013

    Fingerprint

    Heart-Assist Devices
    Transplants
    Survival
    Equipment and Supplies
    Extracorporeal Membrane Oxygenation
    Policy Making
    Proportional Hazards Models
    Transplantation
    Therapeutics

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Surgery
    • Pulmonary and Respiratory Medicine

    Cite this

    Mechanical circulatory support pathways that maximize post-heart transplant survival. / Karamlou, Tara; Gelow, Jill; Diggs, Brian S.; Tibayan, Frederick (Fred); Mudd, James; Guyton, Steven W.; Slater, Matthew; Song, Howard.

    In: Annals of Thoracic Surgery, Vol. 95, No. 2, 02.2013, p. 480-485.

    Research output: Contribution to journalArticle

    @article{02caa4b34db44203a8011ff66e14c442,
    title = "Mechanical circulatory support pathways that maximize post-heart transplant survival",
    abstract = "Background: Heart transplant (HTx) recipients reach transplantation through increasing numbers of support pathways, including transition from one pathway to another. Outcomes of patients successfully bridged with various support pathways are unknown. We sought to identify mechanical circulatory support pathways that maximize survival after HTx. Methods: A supplemented United Network Organ Sharing Dataset tracked status 1 HTx outcomes from 2000 to 2010. Recipients were grouped based on support pathway before HTx, including those transitioning from one pathway to another. Multivariable factors for time-related death were sought using Cox proportional hazard regression models. Results: We identified 13,250 status 1 HTx recipients. Initial support pathways were inotropes (n = 7,607), left ventricular assist device (LVAD [n = 4,034]), intraaortic balloon pump (n = 729), biventricular assist device (n = 521), extracorporeal membrane oxygenation (ECMO [n = 316]), and right ventricular assist device (n = 43). Multivariable analysis demonstrated that LVAD use conferred a survival advantage (hazard ratio [HR] 0.71; p <0.001), whereas all other support pathways, including inotropes (HR 1.1; p = 0.02), right ventricular assist device (HR 1.9; p = 0.01), and ECMO (HR 2.2; p <0.001) increased the risk of post-HTx death. Support pathway transition (both escalation and reduction) occurred in 2,175 patients. Patients who transitioned from either ECMO or biventricular assist device support at listing to LVAD-only support at HTx had improved post-HTx survival that was comparable to patients who had LVAD-only therapy throughout their course (p = 0.74). Conclusions: The LVAD supported HTx recipients have better posttransplant survival than patients after all other mechanical support pathways. Survival after HTx is optimized when ECMO or biventricular assist device support can be transitioned to LVAD-only support. Our findings should aid clinical decision making and inform organ allocation policy development intended to maximize societal benefits of HTx.",
    author = "Tara Karamlou and Jill Gelow and Diggs, {Brian S.} and Tibayan, {Frederick (Fred)} and James Mudd and Guyton, {Steven W.} and Matthew Slater and Howard Song",
    year = "2013",
    month = "2",
    doi = "10.1016/j.athoracsur.2012.05.108",
    language = "English (US)",
    volume = "95",
    pages = "480--485",
    journal = "Annals of Thoracic Surgery",
    issn = "0003-4975",
    publisher = "Elsevier USA",
    number = "2",

    }

    TY - JOUR

    T1 - Mechanical circulatory support pathways that maximize post-heart transplant survival

    AU - Karamlou, Tara

    AU - Gelow, Jill

    AU - Diggs, Brian S.

    AU - Tibayan, Frederick (Fred)

    AU - Mudd, James

    AU - Guyton, Steven W.

    AU - Slater, Matthew

    AU - Song, Howard

    PY - 2013/2

    Y1 - 2013/2

    N2 - Background: Heart transplant (HTx) recipients reach transplantation through increasing numbers of support pathways, including transition from one pathway to another. Outcomes of patients successfully bridged with various support pathways are unknown. We sought to identify mechanical circulatory support pathways that maximize survival after HTx. Methods: A supplemented United Network Organ Sharing Dataset tracked status 1 HTx outcomes from 2000 to 2010. Recipients were grouped based on support pathway before HTx, including those transitioning from one pathway to another. Multivariable factors for time-related death were sought using Cox proportional hazard regression models. Results: We identified 13,250 status 1 HTx recipients. Initial support pathways were inotropes (n = 7,607), left ventricular assist device (LVAD [n = 4,034]), intraaortic balloon pump (n = 729), biventricular assist device (n = 521), extracorporeal membrane oxygenation (ECMO [n = 316]), and right ventricular assist device (n = 43). Multivariable analysis demonstrated that LVAD use conferred a survival advantage (hazard ratio [HR] 0.71; p <0.001), whereas all other support pathways, including inotropes (HR 1.1; p = 0.02), right ventricular assist device (HR 1.9; p = 0.01), and ECMO (HR 2.2; p <0.001) increased the risk of post-HTx death. Support pathway transition (both escalation and reduction) occurred in 2,175 patients. Patients who transitioned from either ECMO or biventricular assist device support at listing to LVAD-only support at HTx had improved post-HTx survival that was comparable to patients who had LVAD-only therapy throughout their course (p = 0.74). Conclusions: The LVAD supported HTx recipients have better posttransplant survival than patients after all other mechanical support pathways. Survival after HTx is optimized when ECMO or biventricular assist device support can be transitioned to LVAD-only support. Our findings should aid clinical decision making and inform organ allocation policy development intended to maximize societal benefits of HTx.

    AB - Background: Heart transplant (HTx) recipients reach transplantation through increasing numbers of support pathways, including transition from one pathway to another. Outcomes of patients successfully bridged with various support pathways are unknown. We sought to identify mechanical circulatory support pathways that maximize survival after HTx. Methods: A supplemented United Network Organ Sharing Dataset tracked status 1 HTx outcomes from 2000 to 2010. Recipients were grouped based on support pathway before HTx, including those transitioning from one pathway to another. Multivariable factors for time-related death were sought using Cox proportional hazard regression models. Results: We identified 13,250 status 1 HTx recipients. Initial support pathways were inotropes (n = 7,607), left ventricular assist device (LVAD [n = 4,034]), intraaortic balloon pump (n = 729), biventricular assist device (n = 521), extracorporeal membrane oxygenation (ECMO [n = 316]), and right ventricular assist device (n = 43). Multivariable analysis demonstrated that LVAD use conferred a survival advantage (hazard ratio [HR] 0.71; p <0.001), whereas all other support pathways, including inotropes (HR 1.1; p = 0.02), right ventricular assist device (HR 1.9; p = 0.01), and ECMO (HR 2.2; p <0.001) increased the risk of post-HTx death. Support pathway transition (both escalation and reduction) occurred in 2,175 patients. Patients who transitioned from either ECMO or biventricular assist device support at listing to LVAD-only support at HTx had improved post-HTx survival that was comparable to patients who had LVAD-only therapy throughout their course (p = 0.74). Conclusions: The LVAD supported HTx recipients have better posttransplant survival than patients after all other mechanical support pathways. Survival after HTx is optimized when ECMO or biventricular assist device support can be transitioned to LVAD-only support. Our findings should aid clinical decision making and inform organ allocation policy development intended to maximize societal benefits of HTx.

    UR - http://www.scopus.com/inward/record.url?scp=84872788599&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84872788599&partnerID=8YFLogxK

    U2 - 10.1016/j.athoracsur.2012.05.108

    DO - 10.1016/j.athoracsur.2012.05.108

    M3 - Article

    C2 - 22921240

    AN - SCOPUS:84872788599

    VL - 95

    SP - 480

    EP - 485

    JO - Annals of Thoracic Surgery

    JF - Annals of Thoracic Surgery

    SN - 0003-4975

    IS - 2

    ER -